Results 71 to 80 of about 306,104 (338)
A Universal Biomimetic Approach for Making Artificial Antigen‐Presenting Cells for T Cell Activation
Advanced Functional Materials, EarlyView.This study shows a biomimetic silica microcapsule (SMC) fabrication method under mild conditions for making artificial antigen‐presenting cells (aAPCs). Inspired by marine biomineralization, peptide‐mediated biosilicification enables silica shell formation on emulsion templates. The resulting SMCs possess a core–shell structure, controlled fluorescence
Fei Hou +5 more
wiley +1 more source
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
Journal of Translational Medicine, 2005 Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine ...
Yee Cassian
doaj +1 more source
Advanced Functional Materials, EarlyView.Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang +9 more
wiley +1 more source
Transducer Materials Mediated Deep Brain Stimulation in Neurological Disorders
Advanced Functional Materials, EarlyView.This review discusses advanced transducer materials for improving deep brain stimulation (DBS) in neurological disorders. These materials respond to light, ultrasound, or magnetic fields, enabling precise, less invasive neuromodulation. Their stimulus‐responsive properties enhance neural control and adaptive therapy, paving the way for next‐generation ...
Di Zhao +5 more
wiley +1 more source
Immunotherapy for Glioblastoma: Adoptive T-cell Strategies
Clinical Cancer Research, 2018 Glioblastoma (GBM) is a devastating disease with an extremely poor prognosis. Immunotherapy via adoptive cell transfer (ACT), especially with T cells engineered to express chimeric antigen receptors (CAR), represents a particularly promising approach ...
Bryan D Choi +3 more
semanticscholar +1 more source
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Vaccines, 2015 Recent studies have demonstrated great therapeutic potential of educating and unleashing our own immune system for cancer treatment. However, there are still major challenges in cancer immunotherapy, including poor immunogenicity of cancer vaccines, off ...
Yuchen Fan, James J. Moon
doaj +1 more source
Advanced Functional Materials, EarlyView.The pre‐internalization phase of endocytosis remains poorly characterized at single‐cell levels. Single‐cell pre‐internalization mechanics are investigated using advanced robotic techniques. Cancer cells exhibit biphasic adhesion – rapid initial binding followed by reinforcement – while fibroblasts show gradual engagement.
Houari Bettahar +6 more
wiley +1 more source
Adoptive immunotherapy for myeloid malignancies [PDF]
Leukemia Supplements, 2014 In allogeneic stem cell transplantation (allo-SCT), much of the anti-tumor effect is derived from a graft versus tumor (GVT) response that is dependent on donor cell engraftment. In order to attain engraftment large doses of chemotherapy are administered to suppress the host's immune system.
openaire +3 more sources
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, EarlyView.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
CD34 selected alloPBSCT and adoptive immunotherapy [PDF]
Bone Marrow Transplantation, 2000 To circumvent aGVHD in the early phase after allogeneic stem cell transplantation but to provide GVL activity later on, we performed alloPBSCT with CD34+ selected grafts followed by delayed add-back of CD3+ T cells. Ten consecutive patients having an HLA-identical sibling donor were enrolled on to this trial. Four patients were in first CR of high-risk
T Fietz +3 more
openaire +3 more sources